Impact of transient androgen deprivation therapy (ADT) with leuprorelin LP 11.25 mg on the histological progression of indolent prostate cancer (PC)–Results of a phase III trial vs active surveillance (AS) impact of transient androgen deprivation therapy (ACT) with leuprorelin LP 11.25 mg on the histological progression of indolent prostate cancer (PC)–results of a phase III trial vs active surveillance (AS)